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ABSTRACT
Objectives: The aim of the study was to evaluate whether the presence of the disease in pregnancy influences the effec-
tiveness and safety of delivery preinduction with prostaglandins:  misoprostol vaginal insert and dinoprostone vaginal gel.
Material and methods: This is a retrospective cohort study conducted of 560 pregnant women. The concomitant diseases 
mainly recorded were diabetes mellitus, hypertensive diseases, intrahepatic cholestasis of pregnancy, asthma, thrombocyto-
penia, and hypothyroidism. The primary study outcome was a successful vaginal delivery. The study above others evaluates 
the time from treatment implementation to the beginning of a labor and to a final delivery, the rate of Cesarean sections, 
and the presence of delivery complications.
Results: Among women with a concomitant disease, Caesarean section was observed more frequently in the misoprostol 
group. In the dinoprostone group, mothers with the concomitant disease as compared to healthy mothers required more 
time to the delivery and to achieve the beginning of labor. There were no differences in postpartum complications regard-
less of the prostaglandins, comorbidities or mothers’ age. Neonates of mothers ≥ 35 years old with concomitant disease 
had lower average Apgar scores.  
Conclusions: Our study showed that comorbidities seem to increase the caesarean section risk in the misoprostol preinduc-
tion group but in the dinoprostone group they prolong the time needed to achieve an active labour phase and a delivery.
Key words: comorbidities; dinoprostone; labor induction; misoprostol
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INTRODUCTION
In the era of postponing pregnancy to an advanced 
age of women, which has both social and economic deter-
minants, various consequences of such decisions must be 
considered. Among older pregnant women, especially over 
40 years old, the risk of comorbidities increases [1]. 
Hypertension in pregnancy concerns 6–10% of preg-
nancies [2, 3]. It is associated with numerous complications 
during pregnancy [4, 5]. The delivery beyond 37 weeks’ 
gestation in pregnancies with the mild hypertensive disease 
was associated with improved maternal outcomes [6]. It has 
been proven, that labour induction at 38 or 39 weeks in 
pregnant women with uncomplicated chronic hypertension 
appears to reduce the risk of serious neonatal morbidity 
and mortality [7]. 
It is well known that diabetes type II is highly correlated 
with obesity and unfortunately obesity among women of 
reproductive age (20–39 years) increases, which altogether 
is concerning [8–9]. Obesity is a popular risk factor for still-
birth [10]. Fetal hypertrophy may lead to a disproportion 
of labour, shoulder dystocia during delivery, the need for 
urgent caesarean section with an increased risk of preop-
erative complications [11]. Both maternal gestational dia-
betes mellitus and obesity are independently associated 
with an unfavourable course of pregnancy and both have 
an even greater impact than either one alone [12]. In order 
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to reduce the risk of fetal complications in pregnancy with 
pregestational diabetes and gestational diabetes, Polish 
Gynaecological Society recommends labour induction after 
38 weeks and after 39 weeks of gestation, respectively [13].
Pregnant women older than 35 years have also increased 
risk of placenta previa, placental abruption or preterm birth 
and small-for-gestational age neonates. When comparing 
the adjusted perinatal mortality rates between women aged 
20–24 with 35–39 and 40 years old, the rates were 63% 
(p = 0.04) and 183% (p = 0.01), respectively. Also, the rates 
of the adjusted perinatal mortality and morbidity rates were 
much higher in over 35 years-old pregnant group compar-
ing with women under 25 years old [14]. There is the real 
risk of stillbirth in pregnant women aged 40 and more and 
that is why The Polish Society of Gynecologists and Obstetri-
cians recommends to treat those pregnancies as biologically 
mature and to induct labour at 39 weeks of gestation [13]. 
As mentioned above there are studies showing the need 
for active rather than expectant management according to 
varies pregnancy complications and finishing the pregnancy 
before 40 weeks of gestation. The choice of the method, 
in accordance with the recommendations of The Polish 
Society of Gynecologists and Obstetricians, is based mainly 
on the assessment of obstetric state in each patient, the 
preferences of the deciding physician and, most often, 
the availability of a given procedure in a hospital.
The crucial role plays the maturity of the cervix mostly 
assessed by scale introduced by Bishop in 1964 [15]. There 
are many possible ways of preparing the cervix to the 
delivery which is called a labour pre-induction. The most 
often used ones include the mechanical ways (a Foley 
or a double-balloon catheter, membrane stripping) and 
the pharmacological way with the usage of prostaglan-
dins in a numerous dosage and routs of administration 
(dinoprostone-prostaglandin E2 and misoprostol-pros-
taglandin E1) [16]. 
Available research results show effectiveness and safety 
of a use of prostaglandins for preinduction purposes, after 
a control for several covariates, and, as mentioned above, 
there are several clinical characteristics of the pregnant 
woman which are indications for the use of preinduction. 
The knowledge, however, on how the presence of a disease 
in pregnant woman influences clinical outcomes in those 
patients is very limited.
Objectives
The aim of the study was to evaluate whether the pres-
ence of the disease in pregnancy influences the effective-
ness and safety of prostaglandins which are the most often 
used in routine clinical practice for preinduction, meaning: 
the misoprostol vaginal insert at a dose of 0.2 mg (Misodel, 
Ferring Pharmaceuticals Poland sp. z o.o) and dinoprostone 
gel at a dose of 0.5 mg (Prepidil, Pfizer Polska Sp. z o.o.). 
In details, the study assessed whether the presence of dis-
ease influences the effectiveness of the two aforementioned 
drugs measured by the time from treatment implementa-
tion to the beginning of a labour and to a final delivery and 
safety measured by the rate of emergency Caesarean sec-
tions, the presence of delivery complications, and some 
health indicators in newborns. Additionally, we addressed 
an issue of mothers’ age as a potential contributing factor.
MATERIAL AND METHODS
The study included 560 pregnant women hospitalized 
at the Obstetric and Perinatology Department at the Uni-
versity Hospital in Cracow between January 2015 and April 
2019. This was a retrospective cohort design for which all 
available medical records had been identified and reviewed. 
The list of collected information covered among others: ma-
ternal age, body mass index (BMI), number of pregnancies, 
parity history, gestational age. The mode of delivery, indica-
tions for caesarean section and other maternal outcomes 
including, episiotomy, anemia requiring blood transfusion, 
uterine hyperstimulation were also counted.
All patients identified as eligible for the study had to 
have singleton gestation with cephalic presentation and 
they required labour induction for medical indications. 
The cervical ripening was performed with dinoprostone gel 
or misoprostol insert. There were no known selection rules 
implemented by physicians at a clinic which might favor 
the use of one drug over the other due to patient’s char-
acteristics or preferences. Other inclusion criteria were the 
Bishop’s score ≤ 4 and an absence of an active labour before 
administration of the drug. Exclusions included expected 
fetal weight over 4500 g or any known contraindication to 
vaginal delivery, or any contraindication for prostaglan-
dins. For the presented study, pregnant women with any 
diagnosed disease were included. These were mainly: any 
tape of diabetes mellitus, hypertensive diseases, intrahe-
patic cholestasis of pregnancy, asthma and thrombocyto-
penia, hypothyroidism.
The primary study outcome was a successful vaginal 
delivery. Secondary effectiveness outcome measures were 
time from drug administration to delivery (both, vaginal 
and Caesarean section), induction-active labour inter-
val time and durations of the first three delivery stages. 
The safety outcomes covered any complication observed 
during a labor such as blood transfusion, uterine hyper-
stimulation, curettage after delivery, episiotomy, rupture of 
perineum, and additionally emergency Caesarean delivery.
Statistical analysis
For the purpose of the study, all participants have 
been classified into two groups, a dinoprostone and 
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a misoprostol group. The categorization was made by the 
implementation of the intention to treat (ITT) principle. 
Thusly, mothers who were intended to begin their labour 
with dinoprostone and received dinoprostone as a first 
drug after admission were categorized as dinoprostone 
group members, and those who received misoprostol first 
composed a misoprostol group. There was also a group of 
women, in which, in the lack of effect of one drug, the other 
had been implemented. These were included according 
to the intention to treat (ITT) criteria in the appropriate 
group in the effectiveness analyses and additionally were 
analyzed as a separate group when complications were 
considered.
The descriptive characteristics of the investigated 
groups have been presented by the mean, SD, median and 
first (Q1) and third quartile (Q3). Median and quartiles 
were used as majority of data distributions were skewed 
causing the mean and SD were not informative enough 
to provide appropriate group depiction. To test wheth-
er there were differences in the study outcomes across 
analyzed groups the following strategy had been imple-
mented for categorical data: 1. a chi-square test was used 
provided the expected values exceeded 5, otherwise, the 
Fisher’s exact test was used; 2. to test whether there is a dif-
ference between mothers with a disease as compared to 
mothers without a disease across strata by mother’s age (< 
35 yrs vs 35 + yrs) the Cochran-Mantel-Haenszel statistics 
were used. This answered a question of whether the effect 
size caused by the presence of a disease across the two 
treatments differed between younger and older mothers. 
For continuous data: 1. firstly, the assumption of normal 
distribution had been tested using Shapiro-Wilk test; 2. as 
the variables analyzed were skewed the U-Mann-Whit-
ney test was used to test for significance of a difference. 
The results with a p < 0.05 were considered statistically 
significant. The pairwise procedure was used for missing 
data, consequently all the available data were used for 
analyses. All analyses had been made by the IBM SPSS 
Statistics, version 26.
RESULTS
There were 560 women identified as admitted for 
a labour induction in the calendar period covered by the 
study. In this group, the misoprostol insert was applied to 
210 pregnant women, and dinoprostone gel was used in 
350 patients. In the dinoprostone group 100 women, who 
received additionally misoprostol as a second drug, were 
identified. In total, there were 320 women with at least one 
diagnosed disease 117 in the misoprostol and 203 in the 
dinoprostone group. Out of these 57 and 87, respectively, 
were diagnosed with hypothyroidism, 27 and 28 with hy-
pertension, 23 and 65 had diabetes, 3 and 15 had both, 
diabetes and hypertension, and 7 and 8 had some other 
diseases. Women diagnosed with any concomitant disease 
had higher body mass and higher BMI in both dinoprostone 
and misoprostol groups. Women representing 35 + age 
category characterized a higher number of pregnancies. 
All the other characteristics were similar across analyzed 
groups (Tab. 1 and 2).
Among women with concomitant disease vaginal 
delivery was observed more frequently in the dinopros-
tone group as compared to misoprostol (66.5% vs 52.1%, 
p = 0.013). Consequently, Caesarean sections were observed 
more frequently in the misoprostol group. Moreover, moth-
ers with a disease treated by misoprostol as compared to di-
noprostone more frequently were referred to Caesarean sec-
tion in emergency (Tab. 3). When we took into account the 
misoprostol group only, a higher proportion of pregnant 
women with a concomitant disease (as compared to women 
without the disease) underwent Caesarean section (47.9% 
vs 31.2%; p = 0.016), and also more of them experienced 
emergency Caesarean section (being a part out of total 
deliveries) (35.9% vs 20.4%; respectively, p = 0.015). Those 
differences were not observed in the dinoprostone group 
(Tab. 3). Some detailed analysis of Caesarean indications 
revealed that pregnant women with a disease treated by 
misoprostol more frequently presented preeclampsia and 
placenta abruption (both, when they were compared with 
mothers with a disease treated by dinoprostone, and 
with mothers treated by misoprostol but having no con-
comitant disease) (Tab. 3).
There were no differences in postpartum complica-
tions in the group of study participants regardless of the 
prostaglandin combination, any concomitant disease, or 
mothers’ age, apart from more often need for episiotomy 
and an occurrence of rupture of perineum in dinoprostone 
group. (Tab. 4a and 4b).
Interesting findings are shown in Table 5 with time inter-
vals from drug implementation to delivery (vaginal only or 
any delivery). It has been observed that in the group treated 
by dinoprostone, mothers with the concomitant disease as 
compared to mothers without the disease required more 
time to the delivery (vaginal route only: 39.6 vs 31.3 hours, 
p = 0.014, or any rout: 42.8 vs 35.6 hours, p = 0.023) and to 
achieve the beginning of a labor (33.5 vs 25.3, p = 0.009). 
After analysis of mothers’ age, we have found no differ-
ences. In the misoprostol group, no significant differences 
in time intervals were found. The investigation of dino-
prostone – misoprostol differences analyzed in the con-
comitant disease group we noticed that the time from the 
drug implementation to the onset of regular contraction 
activity of the uterus and to the delivery of the newborn 
was shorter for misoprostol as compared to dinoprostone 
and the differences were statistically significant (Tab. 5). 
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Interestingly, there were no significant differences observed 
between investigated drugs in the duration of the 1st, 2nd, 
and 3rd stage of labor. The effect of age was noticed in the 
dinoprostone group only (Tab. 5).
Finally, neonatal outcomes were analyzed. In the Apgar 
score analyses the only statistically significant difference was 
found in the group of mothers with a disease treated by 
misoprostol, as in this group older (35 +) mothers delivered 
babies with lower Apgar scores on average (9.0 vs 9.7 pts, 
p < 0.001) and additionally, significantly higher proportion 
of babies with a score of  ≤ 6 (7.4% vs 2.2%) and Apgar 
7–8 (22.2% vs 3.3%) was observed (Tab. 6).
DISCUSSION
The comorbidities in a pregnant woman, like hyperten-
sion, diabetes mellitus, alloimmune disease, intrahepatic 
cholestasis or renal disease, may be a serious medical con-
ditions influencing a wellbeing of a woman and her baby. 
The states mentioned are often indications for a labour 
induction. The several national obstetrical associations have 
established recommendations for most common diseases 
pointing out the need of the elective and active manage-
ment before the due date at 40 weeks of gestation in order 
to reduce the perinatal and maternal risk [13,17–19]. There 
is still an open question, however, about the best (the saf-
Table 1. Clinical characteristics of the study “ITT dinoprostone group” across study participants
No concomitant disease Any concomitant disease
Whole group
[n = 147]































































































Number of pregnancies, n (%)
1 97 (66.0%) 89 (74.8%) 8 (28.6%) 130 (64.0%) 113 (68.9%) 17 (43.6%)
2 27 (18.4%) 20 (16.8%) 7 (25.0%) 47 (23.2%) 37 (22.6%) 10 (25.6%)
≥ 3 23 (15.6%) 10 (8.4%) 13 (46.4%) 26 (12.8%) 14 (8.5%) 12 (30.8%)
Parity history (current delivery included), n (%)
1 112 (76.2%) 99 (83.2%) 13 (46.4%) 155 (76.4%) 134 (81.7%) 21 (53.8%)
2 24 (16.3%) 17 (14.3%) 7 (25.0%) 34 (16.7%) 25 (15.2%) 9 (23.1%)
≥ 3 11 (7.5%) 3 (2.5%) 8 (28.6%) 14 (6.9%) 5 (3.0%) 9 (23.1%)
Nulliparous, n (%) 111 (75.5%) 100 (84.0%) 11 (39.3%) 151 (74.4%) 129 (78.7%) 22 (56.4%)
Miscarriage history, n (%)
no 120 (81.6%) 103 (86.6%) 17 (60.7%) 169 (83.3%) 137 (83.5%) 32 (82.1%)
yes 27 (18.4%) 16 (13.4%) 11 (39.3%) 34 (16.7%) 27 (16.5%) 7 (17.9%)
Pre-ripening cervical characteristics, n (%)
Dilatation ≤ 1 cm 138 (93.9%) 114 (95.8%) 24 (85.7%) 191 (94.1%) 154 (93.9%) 37 (94.9%)











































*p < 0.05 by the Shapiro-Wilk test for normal distribution; #at a time of administration of the first dose of the drug
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est, and effectively leading to vaginal birth) way of a labour 
induction in a specific clinical situation. Several of obser-
vational studies have suggested that induction of labour 
at term is associated with reduction of perinatal mortality 
and morbidity and maternal complications [20] without 
increasing the Caesarean rate risk [21–22].
In our investigation we tried to reveal whether one of 
the two prostaglandins, dinoprostone or misoprostol, pre-
ponderate the other considering effectiveness and safety 
in high-risk pregnancy. Our study showed statistically 
important differences in Caesarean section rate and time 
intervals from drug implementation to delivery between 
groups. Our findings, however, are difficult to compare with 
other results, as, by our knowledge, there are no such studies 
published. The study investigated pregnancies with dif-
ferent kinds of complications presented that misoprostol 
usage in a group of small-for-gestational age neonates at 
delivery was not associated with an increased risk of Cae-
sarean section when compared with dinoprostone or Foley 
catheter preinduction. The authors concluded then, that all 
investigated cervical ripening agents had similar efficacy 
and safety in small-for-gestational age pregnancies which is 
not in consistence with our results [23]. On the other hand, 
literature data indicate an increased risk of Caesarean sec-
Table 2. Clinical characteristics of the study “ITT misoprostol group” across study participants
No concomitant disease Any concomitant disease
Whole group
[n = 93]






























































































Number of pregnancies, n (%)
1 52 (55.9%) 45 (61.6%) 7 (35.5%) 74 (63.2%) 58 (64.4%) 16 (59.3%)
2 20 (21.5%) 16 (21.9%) 4 (20.0%) 23 (19.7%) 17 (18.9%) 6 (22.2%)
≥ 3 21 (22.6%) 12 (16.4%) 9 (45.0%) 20 (17.1%) 15 (16.7%) 5 (18.5%)
Parity history (current delivery included), n (%)
1 64 (68.8%) 54 (74.0%) 10 (50.0%) 95 (81.2%) 75 (83.3%) 20 (74.1%)
2 18 (19.4%) 14 (19.2%) 4 (20.0%) 17 (14.5%) 12 (13.3%) 5 (18.5%)
≥ 3 11 (11.8%) 5 (6.8%) 6 (30.0%) 5 (4.3%) 3 (3.3%) 2 (7.4%)
Nulliparous, n (%) 62 (66.7%) 53 (72.6%) 9 (45.0%) 88 (75.2%) 70 (77.8%) 18 (66.7%)
Miscarriage history (n, %)
no 70 (75.3%) 57 (78.1%) 13 (65.0%) 89 (76.1%) 67 (74.4%) 22 (81.5%)
yes 23 (24.7%) 16 (21.9%) 7 (35.0%) 28 (23.9%) 23 (25.6%) 5 (18.5%)
Pre-ripening cervical characteristics, n (%)
Dilatation ≤ 1 cm 86 (92.5%) 69 (94.5%) 17 (85.0%) 108 (92.3%) 83 (92.2%) 25 (92.6%)










































*p < 0.05 by the Shapiro-Wilk test for normal distribution; #at a time of administration of the first dose of the drug
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tion in women with pre-eclampsia in the dinoprostone 
induced labour group, regardless of the number of deliveries 
and gestational age, but no differences were found in the 
group with hypertension without pre-eclampsia and in the 
group without hypertensive diseases at all [24]. This is in 
conformity with our data showing no differences according 
to presence of concomitant disease in dinoprostone group. 
There were also no differences in the risk of Caesarean sec-
tion, depending on the gestational age in the dinoprostone 
induced group of women with gestational hypertension 
[25]. In view of these results, we speculate that the higher 
rate of Caesarean rate in the misoprostol group might be 
related to the comorbidity of pregnant women with no such 
effect in the dinoprostone group.  
No differences were found in perinatal outcomes when 
misoprostol was used in the groups with and without hyper-
tensive diseases [26] as well as the dinoprostone insert did 
not adversely affect the perinatal outcomes compared to the 
group of women with spontaneous or oxytocin-stimulated 
delivery in the group of women with hypertension [27]. In 
our study, only babies in the subgroup of mothers over 
35 years old with any concomitant disease had statisti-
cally significant lower average Apgar scores comparing 
with younger mothers with comorbidities. These findings 
require more detailed analyses on larger study groups. Re-
garding the neonatal safety of a preinduction of a labour in 
a pregnancy with any comorbidity, because only the Apgar 
points at the first minute were assessed, we cannot draw 
a definite conclusion. Nevertheless, the data we have gained 
show no differences in Apgar score between dinoprostone 
and misoprostol in any concomitant disease groups.
In our study we did not find significant differences in 
postpartum complications among pregnant women with 
any concomitant disease after labour induction using ei-
ther dinoprostone or misoprostol, what is similar to other 
retrospective study concerning the induction of labour in 
hypertensive and normotensive patients with misoprostol 
and dinoprostone vaginal inserts. The authors also showed 
no differences in time to achieve active labour or to overall 
delivery when considering such confounding variables as 
BMI, gestational age, Bishop’s scale or the time from drug 
administration to the active phase of labour [28]. Neverthe-
less, they showed that women with hypertension need more 
time to achieve active labour or overall delivery both in 
misoprostol and dinoprostone groups. Similarly, it has been 
proven that pregnant women with diabetes need more time 
to maturation of the cervix measured by the Bishop scale 
and simply need a longer time to reach the active stage of 
Table 4b. Postpartum complications among study participants in the group receiving both drugs (i.e. dinoprostone and misoprostol)
Dinoprostone followed by misoprostol
No concomitant disease 
[n = 39]
Any concomitant disease 
[n = 61]
No disease vs any concomitant disease
Mothers < 35 y [n = 89] Mothers 35 + [n = 11]
Any complication
23.1% 16.4% 15.2% vs 14.3% 66.7% vs 40.0%
pchi2 = 0.282 PMH = 0.824
Blood transfusion
5.1% 4.9% 3.0% vs 3.6% 16.7% vs 20.0%
PF=0.999 PMH=0.780
Uterine hyper-stimulation
5.1% 0% 3.0% vs 0% 16.7% vs 0%
PF = 0.150 PMH = 0.400
Curettage after delivery
7.7% 9.8% 9.1% vs 10.7% 0% vs 0%
PF = 0.999 PMH = 0.906
Episiotomy
43.6% 37.7% 48.5% vs 41.1% 16.7% vs 0%
pchi2 = 0.676 PMH = 0.521
Rupture of perineum (any 
type)
10.3% 14.8% 9.1% vs 14.3% 16.7% vs 20.0%
pchi2 = 0.561 PMH = 0.
Rupture of perineum
No rupture 89.7% 85.2% 90.9% vs 85.7% 83.3% vs 80.0%
I-stage 7.7% 13.1% 9.1% vs 12.5% 0% vs 20.0%
II-stage 0% 1.6% 0% vs 1.8% 0% vs 0%
III-stage 2.6% 0% 0% vs 0% 16.7% vs 0%
PF = 0.471 #
chi2 — the chi-squared test with 1 degree of freedom; F — the exact Fisher’s test; # — due to no data in all contingency tables the p-value for the common odds ratio has 
not been estimated; MH — the Cochran-Mantel-Haenszel statistics
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a labor, but without differences in its duration. The study 
also showed that women with diabetes needed a statistically 
significant longer time to give birth after administration of 
prostaglandins when compared to women without diabetes 
regardless the prostaglandin used [29]. Both cited studies 
are partially in agreement to our study showing pregnant 
women with any concomitant disease need statistically 
more time from drug application to the beginning of labour 
or to the delivery in dinoprostone preinduction group with 
the opposite, but not statistically important, observations 
in misoprostol group. The present analysis of women with 
comorbidities undergoing labour preinduction using mis-
oprostol vaginal inserts showed strong statistical differences 
in time intervals from drug implementation to active phase 
achievement and to delivery when comparing with dino-
prostone gel. That may lead to the conclusion of obtaining 
a faster effect of misoprostol used in the group of pregnant 
women with concomitant diseases.
Our study has several strengths, as the access to the data 
enables us to analyze a fair number of pregnant women, 
which increases the power of the study, the analysis of clini-
cal data using cohort retrospective design provided an op-
portunity to assess effectiveness rather than efficacy, but 
in that way provided information on how the investigated 
treatments lead to the effect in real clinical practice. Next, 
we were able to analyze the clinical features of mothers 
and her babies which provided information on safety. An 
additional benefit is the ability to analyze the effects across 
the mother’s age categories.
The provided results however are not free from some 
limitations, as mothers with a disease were investigated 
as one group, but the group was represented by different 
comorbidities. Primarily, we believed, that our investiga-
tion would be able to answer whether there is an effect of 
concomitant diabetes or hypertension in pregnancy on the 
pregnancy outcomes if labour induction took place, but due 
to the limited number of women with these comorbidities, 
we could not provide reliable answers. Additionally, our 
study is a retrospective cohort which, due to lack of rand-
omization, may be a source of bias.
CONCLUSIONS
The presented study has shown that concomitant dis-
ease during pregnancy may have an impact on some safety 
and effectiveness outcomes. Pregnant women with a dis-
ease compared to healthy ones had higher risk of Caesar-
ean section if were treated by misoprostol, however, this 
effect was not observed for dinoprostone. On the other side, 
the presence of a disease caused the time between drug 
implementation and delivery was longer if dinoprostone 
was used. Dinoprostone was also more beneficial than mis-
oprostol to get vaginal delivery if these two drugs were 
compared exclusively in the group of mothers with a disease. 
Considering child’s health, the presence of a disease and 
mother’s age over 35 was associated with lower Apgar scores 
if preinduction method was by misoprostol.
Although, our results are novel in this area, and require 
further investigation, we believe, they may help clinicians to 
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